Tivic Health Systems (TIVC) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
12 Mar, 2026Opening remarks and agenda
Management highlighted the company's transformation from consumer health tech to a vertically integrated immunotherapeutics firm, emphasizing the strategic impact of recent acquisitions and the focus on execution in 2026.
Specific resolutions to be voted on
No explicit voting resolutions were discussed during the meeting.
Board and executive committee updates
CEO Jennifer Ernst led the call, providing updates on strategic direction and operational changes.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tivic Health Systems
- Shifted to immunotherapy, expanded manufacturing, and improved cash position despite higher losses.TIVC
Q4 202525 Mar 2026 - Advancing late-stage biologics for radiation and oncology with major milestones ahead.TIVCInvestor presentation12 Mar 2026
- Shareholders to vote on major equity issuances and incentive plan expansion at special meeting.TIVCProxy Filing9 Feb 2026
- Gross margin rose to 42% and net loss narrowed as VNS advances and cost cuts take hold.TIVCQ2 20242 Feb 2026
- Biopharma pivot with Entolimod, in-house manufacturing, and $75M financing targets dual markets.TIVCEmerging Growth Conference 8922 Jan 2026
- Entolimod and Entolasta drive a late-stage pipeline for radiation and oncology with strong differentiation.TIVCInvestor presentation22 Jan 2026
- Promising non-invasive bioelectronic therapies and strong clinical progress signal growth ahead.TIVCMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- Q3 revenue dropped 56%, losses persist, and new capital is urgently needed.TIVCQ3 202414 Jan 2026
- Acquisition and vertical integration drive cost savings, growth, and new revenue streams.TIVCInvestor Update12 Jan 2026